


Health Care & Biotechnology Sector Profile



Jun-11 Mkt Cap \$49.1b Number of companies: 147 12 month index performance 5.2%


Overview

The listed Health Care sector represents a diverse range of companies including major Australian success stories in pharmaceuticals, biotechnology, medical practice and pathology operators, as well as junior life sciences and medical device companies. The large cap end of the spectrum features well-known names such as CSL, Resmed, Cochlear and Ansell, as well as health care operators such as Sonic, Primary and Ramsay. The smaller cap end of the sector largely consists of junior biotechnology and medical device companies in various stages of research, development and commercialisation as well as suppliers to the health care industry.




Source: IRESS

Value Traded - Health Care, monthly \$billion




Market Capitalisation by Industry Sector

% of Companies by Head Office - Health



Monthly Equity Capital Raising - Health Care, \$billion raised



Recent IPOs

ASX Code	Company Name	Capital Listed, \$m	Lead Manager/s
RVA	Reva Medical, Inc	\$335.3	Inteq Limited
CBZ	CBIO	\$60.5	Novus Capital
PVT	Provet Holdings	\$58.8	RBS
FLS	Fluorotechnics	\$18.8	BBY
GBI	Genera Biosystems	\$16.3	Domain Capital
BNC	Bioniche Life Sciences Inc.	\$12.5	Taylor Collison
AYX	Austofix Group	\$7.6	Leyland

Top Subsequent Issuers FY11

ASX Code	Company Name	Capital Raised, \$m
PRY	Primary Health Care	\$172.4
MSB	Mesoblast	\$123.3
RMD	Resmed Inc	\$54.1
UNS	Unilife Corporation	\$37.4
PRR	Prima Biomed	\$33.4
QRX	QRX Pharma	\$19.8
FPH	Fisher & Paykel Healthcare	\$19.1
STI	Stirling Products	\$16.2
CBZ	CBIO	\$15.5
TIS	Tissue Therapies	\$15.2

ASX Code

ASX Code	Company Name
CSL	CSL
SHL	Sonic Healthcare
RMD	Resmed Inc
COH	Cochlear
RHC	Ramsay Health Care
MSB	Mesoblast
ANN	Ansell
PRY	Primary Health Care
FPH	Fisher & Paykel Healthcare
SIP	Sigma Pharmaceuticals
ACR	AcruX
BKL	Blackmores
SPL	Starpharma
CST	Celastis
RVA	Reva Medical, Inc
SRX	Sintex Medical
PRR	Prima Biomed
CXS	Chemgenex Pharmaceuticals
UNS	Unilife Corporation
QRX	QRX Pharma
PXS	Pharmaxis
BNO	Bionomics
NAN	Nanosonics
BTA	Biota
ISF	iSoft Group
UBI	Universal Biosensors, Inc.
API	Australian Pharmaceutical Industries
ACL	Alchemia
POH	Phosphagenics
HIN	Heartware International
TIS	Tissue Therapies
CBZ	CBIO
IPD	Impedimed
GTG	Genetic Technologies
MYX	Mayne Pharma Group Limited
ONT	1300 Smiles
MOD	Medical Australasia
SHC	Sunshine Heart, Inc.
ADO	Anteo Diagnostics
PBT	Prana Biotechnology
SOM	Somnomed
CUV	Clinuvel Pharmaceuticals
CEO	C @
CLV	Clover
SLA	Solagran
VLA	Viralytics
AVX	Avexa
PVA	Psivida Corp
BRC	Brain Resource
PYC	Phylogica
GXL	Greencross
CIR	Circadian Technologies
BLT	Benitec
OBJ	Avita Medical
AVH	Medical Developments International
MVP	Calzada Limited
CZD	Patrys
PAB	Living Cell Technologies
LCT	SDI
IMC	Immuron
ACG	Atcor Medical
NRT	Novogen
PBP	Probiotec
PME	Pro Medicus
AJJ	Asian Centre for Liver Diseases and Transpla
BIT	Biotron
VSC	Vita Life Sciences
ELX	Ellex Medical Lasers
IDT	IDT Australia
CBB	Cordlife
CXD	Cathrx
EMS	Eastland Medical Systems
CMP	Compumedics
GBI	Genera Biosystems
NLS	Narhex Life Sciences
CAJ	Capitol Health
ALT	Analytica
UCM	Uscom
CGS	Cogstate
HCG	Helicon Group
PHG	Pulse Health
KSX	Karmelsonix
AGX	Agenix
MLA	Medical Australia
BNC	Bioniche Life Sciences Inc.
HCT	Holista Coltech
PNO	Pharmanet Group
ITD	ITL
PAA	Pharmaust
BTC	Biotech Capital
BPO	Bioprospect
CDY	Cellmid
NEU	Neuren Pharmaceuticals
CMQ	Chemeq
MVQ	Medivac
CYC	Cyclopharm
OIL	Optiscan Imaging
AMT	Advanced Surgical Design & Manufacture
BDM	Biodym

Top 100 Companies*

Mkt Cap	Brief Description
\$17,454 m	Pharmaceuticals, Vaccines & Plasma Products
\$4,999 m	Medical Diagnostics
\$4,436 m	Sleep and Respiratory Medicine
\$4,086 m	Manufacture and Sale of Cochlear Implant Systems
\$3,674 m	Owner and Operator of Private Hospitals
\$2,420 m	Stem Cell Technology for Treatment of Orthopaedic Conditions
\$1,883 m	Rubber and Latex Protective Products
\$1,706 m	Medical Services, Daycare Surgery
\$1,103 m	Respiratory Care and Obstructive Apnea
\$625 m	Development and Distribution of Pharmaceuticals
\$564 m	Delivery of Testosterone Replacement Therapies
\$447 m	Development and Marketing of Health Products
\$372 m	Nano-Pharmaceutical Products for the Prevention of STIs
\$306 m	Development and Marketing of Diagnostic Products
\$305 m	Development of medical devices, specifically bioresorbable stent products.
\$273 m	Treatments for Liver Cancer
\$262 m	Therapeutics for Cancer & Infectious Diseases
\$219 m	Drug Development for Treatment of Leukaemia
\$211 m	Manufacture of a Retractable Needle Syringe
\$210 m	Therapies To Treat Disorders of The Central Nervous System
\$192 m	Development of Therapies for Respiratory Diseases
\$191 m	Treatments for Cancer, MS, Anxiety and Epilepsy
\$176 m	Infection Control and Decontamination Technology
\$173 m	Development of Anti-Infective Drugs
\$171 m	Health Information Technology Company
\$162 m	Point-of-Care Medical Diagnostics Devices
\$137 m	Pharmaceutical Distributor
\$117 m	Carbohydrate-Based Molecules for Therapeutic Applications
\$103 m	Biotechnology - Application of Phosphorylation
\$99 m	Devices for Treatment of Heart Failure
\$97 m	Wound Healing, Tissue Repair and Cell Culture Technology
\$96 m	Treatments for Autoimmune Diseases
\$89 m	Diagnostics Devices
\$85 m	Licensing, Genetic Testing and Research
\$79 m	The Testing and Improvement of Generic Drugs
\$76 m	Service Provider to Dentists
\$70 m	Investment in healthcare and medical product businesses
\$54 m	Heart Assist Devices
\$53 m	Commercialising In Vitro Diagnostic Products
\$53 m	Therapeutic Drugs for Age-Related Diseases
\$50 m	Devices for Obstructive Sleep Apnoea and Snoring
\$50 m	Drug Development for UV-Related Medical Disorders
\$47 m	Health Care Distributors
\$47 m	Functional Food Ingredients Containing LCPs
\$45 m	Bio-Medical Products for Treatment of Cirrhosis, Hepatitis
\$43 m	Virotherapy anti-cancer technology
\$36 m	Anti-Infective Pharmaceutical Medicines
\$35 m	Drug Delivery Products in Ophthalmology and Oncology
\$29 m	Commercialising Brain Function Analysis
\$29 m	Biopharmaceuticals - Peptide Therapeutics
\$29 m	Provision of a Network of Veterinary Services
\$27 m	Angiogenesis-Based Therapies for Serious Illnesses
\$26 m	RNA Interference Technology
\$24 m	Pharmaceuticals
\$23 m	Developer of Skin and Burns Treatment
\$23 m	Pharmaceuticals and Medical and Veterinary Equipment
\$23 m	Biomaterials and Metabolic Pharmaceuticals
\$22 m	Development of Natural Human Antibody-Based Therapies
\$22 m	Therapies for Type 1 Diabetes and Neurological Disorders
\$21 m	Manufacture and Distribution of Dental Materials
\$21 m	Oral Immunotherapeutic Products
\$20 m	Devices for Cardiovascular Patient Assessment
\$20 m	Pharmaceuticals, Health Supplements
\$19 m	Contract Manufacturer of Pharmaceuticals
\$18 m	IT Solutions To The Private Medical Market
\$16 m	Treatment of Liver Diseases and Transplantation
\$16 m	Trials, Research and Commercialisation of Anti-Viral Drugs
\$15 m	Supplements, Vitamins, Minerals, Meal Replacement, Nutrition
\$15 m	Ophthalmology
\$15 m	Pharmaceutical Ingredients, Insourcing
\$15 m	Tissue and Cord Blood Banking
\$15 m	Medical Devices - Cardiac Catheters
\$14 m	Injection, Infusion and Blood-Drawing Devices
\$13 m	Computer Based Patient Monitoring and Diagnostic Systems
\$13 m	Molecular Diagnostic Tests
\$12 m	HIV related diagnostics and therapeutic products
\$12 m	Amalgamation of Dental Clinics
\$12 m	Retractable Technologies and Diagnostic Trading
\$11 m	Cardiovascular Function Measurement Devices
\$11 m	The Commercialisation of Computerised Tests of Cognition
\$11 m	Pharmaceuticals and Medical Devices
\$11 m	Private Hospitals, Home Nursing Services and Agencies
\$11 m	Respiratory Diagnostics Technology
\$10 m	Product development in relation to bloodclots
\$10 m	Medical Devices to Prevent Sharps Injuries
\$10 m	Human and Animal Health Products
\$10 m	Development and Commercialisation of Ovine Collagen
\$10 m	Health Care Distributors
\$9 m	Designs and Manufactures Innovative Medical Devices
\$9 m	Contract Chemistry, Life Sciences R&D Outsourcing
\$9 m	Biotechnology Investment Fund
\$9 m	Development of Natural Plant Extracts
\$9 m	Treatments for Cancers and Chronic Inflammatory Diseases
\$9 m	Neuroprotection and Metabolism
\$8 m	CHEMO polymeric antimicrobial and CHEMYDE preservative
\$8 m	Clinical Waste Conversion Technology
\$8 m	Proprietary Lung Radiopharmaceuticals
\$8 m	Miniaturised Confocal Microscopes & Imaging
\$8 m	Prosthetic Implants and Medical Devices
\$8 m	Pharmaceutical Development

*Ranked by market capitalisation. May exclude companies with suspended securities or subject to poor liquidity where mkt cap cannot be determined.

Disclaimer: Independent advice from an Australian financial services licensee is needed before making financial decisions. This is not intended to be financial product advice. ASX Limited ABN 98 008 624 691 and its related bodies corporate and their respective directors, employees, agents, servants and boards accept no responsibility for any person acting on or relying on any opinion, advice or information and, to the extent permitted by law, disclaim all liability for any loss howsoever caused (including by reason of negligence) and for any errors, omissions, defects or misstatements (whether negligent or otherwise) contained in this publication. © Copyright 2011 ASX Limited ABN 98 008 624 691. All rights reserved 2011.